

REVIEW ARTICLE

Nanomedicine: A Review

Varsha Gangwani¹, Bharat Chouhan² 

^{1,2} Department of B. Pharmacy, B.R. Nahata College of Pharmacy, Mandsaur University, Mandsaur (M.P.), 458001, India

Received: 30-11-2022 Revised: 31-12-2022 Accepted: 15-01-2023


ABSTRACT

The clinical use of nanotechnology is called nanomedicine. Nanomedicine combines organic machines with biological devices, molecular nanotechnology, nano-electronic biosensors, and even potential future uses. Depending on the range of its uses, nanomedicine and nanoparticles have different physical, chemical, and mechanical characteristics.

Keywords: Molecular nanotechnology, Nanomaterials, Nanomedicine

INTRODUCTION

Nanomedicine ranges from biological and nanoscale materials used in medical applications to nanoscale electronic biosensors and even potential future uses of molecular nanotechnology combined with organic machinery. In the near future, nanomedicine aims to provide a useful collection of research tools and clinically useful technologies.^[1]



The National Nanotechnology Initiative anticipates new commercial uses for the pharmaceutical sector, including improved drug delivery methods, novel therapies, and *in vivo* imaging. The United

*Corresponding Author:

Varsha Gangwani,
E-mail: gangwani.varsha20@gmail.com

States National Institutes of Health Common Fund program is supporting four nanomedicine development facilities by providing funds for nanomedicine investigations.^[2]


In 2015, the market for nanomedicine generated \$16 billion, with an annual investment in nanotechnology R&D of at least \$3.8 billion. In recent years, global investment in developing nanotechnology increased by 45% per year, with product sales topping \$1 trillion in 2013. The economy is anticipated to be significantly impacted by the nanomedicine sector as it continues to expand.^[3]

DRUG DELIVERY

Using nanoparticles, tablets can now be delivered to specific cells thanks to nanotechnology. By placing the active ingredient in the diseased area only and in no greater amount than desired, the usual drug intake and side effects can be significantly decreased. Targeted drug delivery aims to lessen side effects of medication with parallel drops in consumption and treatment costs.

The usage of nanoengineered devices with a molecular focus may be able to achieve this. Another advantage of adopting nanoscale technology for medical applications is that smaller devices are

less intrusive and may be implanted in the body, and biochemical response times are much faster. These gadgets are quicker and more sensitive than standard drug delivery. The success of the medication's transport to the center of the body, its successful release, and its green encapsulation all contribute to the effectiveness of drug delivery using nanomedicine.^[4]



Lipid- or polymer-based nanoparticles can be used to create drug shipping structures that will enhance the medication's pharmacokinetics and biodistribution. Nanoparticles can be utilized to enhance medicine delivery if they are made to escape the body's defense mechanisms. Innovative medication delivery technologies now allow capsules to pass through cellular membranes and enter cellular cytoplasm. One way that medication molecules can be employed more effectively is through a triggered response.

Medicines are injected into the body, and they only begin to work when they come across a certain symptom. For instance, a medicine with low solubility will be substituted with a drug delivery system that has environments that are both hydrophilic and hydrophobic, increasing the solubility. Drug shipping structures may also be able to prevent tissue damage by controlled drug release, cut medication clearance costs, limit drug distribution, or lessen the impact on tissue other than the intended target. Because to the complex host's sensitivities to nano- and micro-sized materials and the difficulty of targeting particular organs inside the frame, the bio-distribution of these nanoparticles is still imperfect.^[5]

Nonetheless, there is still much work to be done to improve and better understand the potential and constraints of nano-particulate systems. While new research shows that nanoparticles can increase attention and dispersion, understanding the hazards of nano-toxicity is an essential next step in understanding how to employ them in medicine. Nanoparticles are being studied for their potential to reduce antibiotic resistance or for a variety of other antimicrobial purposes.^[6]

HISTORY OF NANOMEDICINE

Nanomedicine is a new field of study. The best research on the potential applications of nanotechnology to medicine, clinical practice, and pharmacology has been done since the 1990s. The field of nanotechnology has only been around for a very long time. Following the development of super-resolution microscopy, these fields of biology, physics, and chemistry advanced together in the 20th century, producing new fields of study such as molecular biology, microelectronics, and biochemistry. Information on nanobiotechnology that examines the composition and operation of cells is relevant to nanomedicine.^[7]

When advanced microscopes were invented at the beginning of the 20th century, the door to the nanocosmos suddenly burst wide, making this research feasible.

Since the 19th century, nano-porous ceramic filters have been employed to isolate viruses. Max Ernst, Ludwig Planck, and Albert Einstein manipulated theoretical evidence that suggested there must be several microscopic bits that according to their own principles around 1900.

The necessary tools for this had yet to be developed, making it impossible to make this trash visible.^[8] In 1902, Richard Zsigmondy and Henry Siedentopf successfully used the light microscope to discern patterns smaller than four nanometers in ruby glasses.^[23] Zsigmondy filed a patent application in 1912 for the immersion light microscope, which made it possible to study the behavior of mixed solutions. Since 1931, the transmission microscope, created with the assistance of Max Knoll and Ernst Ruska, has produced images with


noticeably better resolutions than the delicate microscopes used up until that point. Yet it was Erwin Muller's spherical electron microscope, invented in 1936, and its parallel evolution to the field ion microscope, which let physicists to view individual atoms and their association on a floor in 1951, that first made access to the atomic scale possible. Mobile systems and mobile parts were developed as a result of the usage of the groundbreaking microscopes in biology and chemistry. Understanding of the structure and function of the cell membrane, diffusion approaches, and systematic cellular communication by receptors and antibodies consistent with fixed policies have become ever higher in the subsequent long time thanks to similar innovations, such as the voltage clamp (a precursor of the patch clamp approach). Effective vaccinations advanced as researchers studied the mechanisms that maintain and regulate metabolism, the function of the system, the role of proteins and enzymes, and more.^[9]

The idea of hereditary disorders and the concept of patient-specific, molecularly customized treatments were both inspired by the description and understanding of DNA and RNA in the Nineteen Fifties and Sixties. With the advent of scanning probe microscopy, direct observation in the nano range finally became possible. Gerd

Binnig and Heinrich Rohrer created the scanning tunneling microscope, which was successfully used to graphically display an individual atom in 1981. In 1986, the first atomic pressure microscope was switched on.^[10]

It was possible to place and regulate nanoscale devices in a very controlled manner in addition to precisely demonstrating them using the various scanning probe research techniques. This revealed a multitude of potential applications, and new scientific fields, such nanomedicine, were created that were specifically suited to the nano variety. Norio Taniguchi first used the term "nanotechnology" in 1974, and it is still a legitimate description today: "Nanotechnology primarily covers the processing of separation, consolidation, and deformation of material by way of one atom or one molecule."^[11]

The scientist and chemist award winner Feynman *et al.* predicted in his 1959 work There's lots of area on the all-time low that there would 1 day be nanotechnologies and hence the associated potentialities. a request to enter a brand-new field of physics.^[28] And although though the word "nano" does not appear in it at all anymore, this article has been regarded as the foundational work of nanotechnology. Feynman encouraged us to consider the creation and management of micro-



machines based on the principles of quantum mechanics and foresaw that the development of more precise microscopes would allow for access to the world of individual atoms and the possibility of arranging atoms in the desired configuration. Even the use of tiny medical devices was discussed by him: It would be exciting in surgery if you could swallow the doctor. The mechanical healthcare worker was placed inside the blood vessel, and it is now travelling to the heart and “seeing” about. Once it determines which valve is broken, it chops it out with a small knife. To help a failing organ, additional small machines might be entirely integrated into the frame.^[12]

Following Feynman’s staking out of the new subject of study and the arousal of many scientists’ curiosity, instructions of idea emerged outlining the many possibilities for producing nanostructures. Most of the time, the top-down approach is consistent with Feynman’s feedback on progressive shrinkage within the size of already-built machines and tools. By utilizing physical and chemical methods as well as the self-organizing forces of atoms and molecules, the bottom-up strategy revolves around the building of nanostructures atom for atom. In 1986, after the release of *Engines of Creation*, the concept of “molecular engineering” gained popularity. *The Coming Age of Nanotechnology*. The first and much debated book on nanotechnology, was released. In it, Drexler *et al.* described the development of complex machines from individual atoms that could manipulate molecules and atoms in multiple ways to create things and self-replicate. In their book *Unbounding the Future*, authors Drexler *et al.* explore the potential use of such “nano-bots” or “assemblers” in the pharmaceuticals industry. The term “nanomedicine” was allegedly first used in 1991 as part of the engineering revolution, which was announced at that time. The word first appeared in the book *Nanomedicine* by Freitas *et al.*, which was published in 1999, and has since been used in technical literature. Since the realization of Feynman and Drexler’s visions of nanoscale robots that patrol the body, neutralize disease foci, locate, and repair organs and cells with compromised characteristics is still in the distant future, nanomedicine is primarily focused

on exploring the potential for controlling and manipulating mobile methods, such as through the targeted delivery of energetic materials.^[13,14]

Paul Ehrlich attempted to broaden the concept of “magic bullets” at the beginning of the 20th century by introducing pills that could be used to target specific ailments and would eradicate all germs with only one treatment. He created Salvarsan, who appears to be the first largely acting treatment of this kind and introduces chemotherapy. The development of ever more cutting-edge “magic bullets” became possible because to knowledge gained over the course of the 20th century about cells, their components, intra- and intercellular activities, and cellular communication, as well as advancements in biochemistry and biotechnology. Peter Paul Speiser created the first nanoparticles that could be used for targeted medication therapy at the end of the 1960s,^[32] and Georges J.F. Kohler and Cesar Milstein were successful in creating monoclonal antibodies in the 1970s.^[33] Since then, there has been substantial research into the practical synthesis, applications, and physicochemical functionalization of a variety of carrier architectures. Beginning in the 1990s, nanoparticles were modified for the 1st time to carry genes and pieces of DNA, and they were sluiced into cells using antibodies.^[15]

Specifically, liposomes and micelles are being explored at gift biocompatible polymers as firms for capsules, vaccines, and genes. Nanomaterials are not filtered out of the circulation because of their short length (often <200 nm) and may travel inside the organism until they reach their destination. As “Trojan horses,” active substances can have their hollow interiors and floors modified so that they can cross cellular membranes and other natural barriers.^[16] They can then use biosensors, such as antibodies, to recognize specific cells and tissues, attach to them, and release their energetic materials over an extended period of time. These processes, in addition to being connected to cancer treatment, are intriguing because they allow for the delivery of greater quantities of the material to the damaged tissue while reducing side effects by using controlled release of cytostatics fully within the growing tissue. The enhanced porosity

and retention effect, which was first described by Yasuhiro Matsumura and Hiroshi Maeda in 1986, will also be utilized in cancer treatment supported focused transport of active materials. This effect refers to the fact that nanoparticles are deposited in tumors to a greater extent than in healthy tissue.^[17]

ETHICS OF NANOMEDICINE


The National Institute of Environmental Health Sciences, the National Science Foundation, the National Institute of Occupational Safety and Health, and the U.S. Environmental Protection Agency have released a variety of programs to assess the dangers of nanomaterials. The National Cancer Institute has also set up a lab for analyzing the *in vitro* response to ENM, which will be used in the majority of cancer diagnoses or treatments. The majority of observers concur that for society to fully benefit from applied research, protection and threat issues must be fully recognized.^[18]

Since that nanoparticles have no common properties other than size, evaluating their safety can be a challenging task (1–100 nm). Each type of material needs to be evaluated on its own merits because nanomaterials are not a single class of materials. Nanomaterials may potentially change size or form inside an organism because they will be inextricably linked to their microenvironment. A 100 nanometer particle might wish to disintegrate into a 1 nm fragment, or a 1 nm fragment might combine with another 100 nm particle.^[19]

Studies on animals and tissues have revealed that certain anthropogenetic and obviously degrading

nanoscale substances, including smoke, viruses, diesel exhaust detritus, and infections, activate pathways that counteract toxicity in addition to aerobic stress, infection, and innate and adaptive immune responses.^[20] Nanomaterials are capable of moving from an online promotional page to various body parts. Inhaled nanomaterials will enter the capillaries, and after passing through the circulatory system, they will enter the liver, body fluid nodes, spleen, and bone marrow, just like a few different kinds of materials do. Moreover, nanoscale compounds have the ability to collect in specific physiological regions and have negative effects. The dangers of exposure to nanoscale chemicals typically depend on the route of exposure; for example, a particle that is harmless when swallowed may be lethal when inhaled. Because humans have developed organic defenses for managing natural nanomaterials but not synthetic ones, ENMs, including fullerenes and C60 carbon shells, may be more dangerous to human health than actual nanoparticles.^[21]

Although *in vivo* animal studies and *ex vivo* laboratory investigations will expand our knowledge of various nanomaterials, they will not completely remove the uncertainty surrounding a person's initial exposure to a certain type of nanomedicine product during a phase I clinical trial. According to ethical guidelines and rules, risks to human subjects must be kept to a minimum whenever practical and must be justified given their ability to benefit society and the subjects themselves. Six study participants had severe illness after being given a dose of a protein that was non-



toxic to animals when administered at a dose five hundred times higher. One of those instructions is to exercise extreme caution when interacting with substances that have antibodies and antigens and could cause an immune response.^[22]

If a product has survived the tough phase I clinical trial test and is in phase II or III clinical trials, significant risks might all rise in a similar way. An information and protection monitoring board (DSMB) is needed to keep track of negative behaviors, adverse responses, and other problems with the product under examination to reduce these risks. The DSMB needs to review the data often enough to identify any risky trends and handle any potential harm to human subjects.^[23]

Given the possibility of adverse reactions and unanticipated side effects even after a product has been approved and made available, it is crucial for doctors to report these issues to the relevant safety organization (including the FDA) and for businesses to conduct Phase IV (post-advertising and marketing) studies. Although the FDA will not require businesses to do post-marketing studies, it should keep in mind making this research a requirement for some nanomedicine products. To monitor the protection of some nanomedicine products, lengthy research (5–10 years in length) will be necessary.^[24] One of the drug defense system's weakest links is extended addition and assessment. Because medical trials frequently do not involve enough subjects to identify rare side effects and some health issues require years of exposure to develop, adverse effects from new pharmaceuticals frequently do not manifest until they have been on the market for several years. Governmental corporations must fund studies on the long-term effects of publicity on nanomedicine products because private organizations are not legally compelled to support long-term investigations of the effects in their scientific products.^[25]


A challenging task is conveying the risks of nanotechnology to research subjects and diverse sections of society. According to ethical and legal standards, an investigator must inform a deserving research problem (or his or her consultant) about the study's justification, methods, benefits, risks,

options, confidentiality protections, and any other information the problem might need to decide whether or not to participate. Furthermore, it is frequently forgotten that the main objective of a clinical trial is to develop new knowledge that can benefit other patients, not to provide the best medical supervision for the participants.^[26] It is nerve-wracking for researchers to candidly discuss the benefits and risks of taking part in nanomedicine research during the consent process.^[27] Researchers must warn subjects that there may be risks that are not anticipated if a clinical trial for nanomedicine contains advertising for innovative materials that have not been properly evaluated.^[28] Risk communication with society's members is essential if nanomedicine is to also promote public health and garner support from the general public. Researchers must feel obligated to inform the public about the potential applications of nanotechnology in medicine, as well as on the benefits and potential drawbacks of this field of study. People are more likely to perceive new technology as harmful or disruptive when they are poorly informed about it. The reaction to genetically modified elements in Europe serves as a reminder of the value of involving the general public in a conversation about a new generation.^[29] Several Europeans were angry at this lack of understanding for their opinions and lack of situational safety. Producers and researchers of nanomedicine, as well as government organizations, must educate the public about nanomedicine, expand an integrated program, perhaps partnering with museums, and engage in an open and honest discussion about the ethical, social, and criminal justice issues it exacerbates to prevent future generations from making the same mistakes.^[30]

APPLICATIONS^[31]

Several commercially or in human clinical trials misogynistic nanotechnology-based medications include.

- The Food and Drug Administration initially tested Doxil on Kaposi's sarcoma associated with HIV. The medicine is enclosed in liposomes, which extends its shelf life after




being dispersed. Liposomes are self-assembling, spherical, sealed, and well-balanced lipid bilayer structures that enclose a wringing-wet region. Furthermore, the liposomes contribute to improved functionality and reduce the loss of function that the drug specifically causes in the heart muscles.

- The bureau tested Onivyde, a vesicle-encapsulated form of irinotecan used to treat pathological process cancer, in October 2015.
- The tiniest silica-based nanoparticles are called C-dots (Cornell dots), and they have a size of about 10 nm. An organic dye that is absorbed into the particles causes them to glow. Since 2011, a clinical trial has been running to test the C-dots as a diagnostic tool to help surgeons locate the location of tumor cells.
- A preliminary study used the “Minicell” nanoparticle technology to evaluate medication formulations on patients with advanced, incurable cancer. The epidermal growth factor receptor (EGFR), which is frequently overexpressed in a variety of cancers, is tightened by cetuximab antibodies to act as a “homing” device to the tumor cells. The minicells were constructed from the membranes of mutant bacteria and loaded with paclitaxel and coated with cetuximab. The tumor cells identify the yes-man that the

minicells are descended from, perceive it as an invading microorganism, and swallow it whole. The anti-cancer drug’s payload kills the tumor cells as it enters. The minicell, which has a diameter of 400 nanometers, is more valuable than manufactured particles ready for drug administration. The researchers concluded that because of their bigger size, minicells have the highest profile of adverse effects since they preferentially leak out of porous thoroughbred arteries, where they resemble tumor cells, and do not reach the liver, digestive tract, or skin. This medication is well tolerated by the patients, according to this Phase 1 clinical research. The minicell drug wordage system can be utilized as a platform technology to treat a variety of different tumors with different anti-cancer medications, with the benefit of a lower dose and fewer side effects.

- In 2014, a section 3 start for treating pain and inflammation without undergoing cataract surgery and a section 2 trials for treating dry disease using the nanoparticle loteprednol etabonate were announced.



DEVELOPMENTS IN NANOMEDICINE

Nanoscale therapies rely on manufactured nanoparticles that can package and unhook medicines where they are required.

The European Nano-Characterization Laboratory (EU-NCL), which is supported by the European Union’s Horizon 2020 research and innovation program, has been described by CEA-Leti as a

megacosm.^[32] Its primary goal is to raise the bar for international excellence in the characterization of nanomedicines for diseases such as cancer, diabetes, inflammatory diseases, or infections, and to make it manageable to all organizations developing candidate nanomedicines before their proposal to restrictive agencies to urge the clearance for clinical trials and, later, selling approval. Patrick Boisseau, a director of merchantry expertise in nanomedicine at CEA-Leti and chairman of the European Technology Platform Nanomedicine, said: “As documented in the ETPN White Paper, there is a shortage of infrastructure to promote nanotechnology-based innovation in healthcare (ETPN).” The main problem that groups developing nanotherapeutics run with is nano-characterization. The EU-NCL project will have a major impact on the nanomedicine network since it will improve the tools and goods’ competitiveness while facilitating European law.

To hasten the harmonization of tampering methods across borders, EU-NCL has teamed with the sole global reference facility, the Nanotechnology Characterization Lab of the National Cancer Institute in the US (US-NCL).^[33] Scott E. McNeil, director of US-NCL, said, “We are thrilled to be a part of this cooperation wattle between Europe and the United States.” “We hope that this partnership will contribute to the global standardization of regulatory standards for the medical evaluation and promotion of nanomedicines.” This idea has unbridled potential for using nanotechnologies to defeat cancer and other serious illnesses, without a doubt, in the field.^[34]


In addition, EU-NCL closely cooperates with

national pharmaceutical companies and the European Medicines Agency to continuously adapt its regulatory-tampering services.


Because it will serve as the main transnational infrastructure for the nanomedicine, this mission is vital for Europe. Its objectives are to promote innovation by sharing data and technologies between academic institutions and businesses.^[35]

The difficulty facing EU-NCL is:

- To provide a trans-disciplinary infrastructure for testing that includes a full range of preclinical characterization assays (physical, chemical, *in vitro*, and *in vivo* testing), enabling researchers to fully comprehend the biodistribution, metabolism, pharmacokinetics, safety profiles, and immunological effects of their medicinal nano-merchandise.
- To promote the adoption and application of cutting-edge operating procedures, reference materials, and stringent control for the preclinical characterization of pharmaceutical nanoproducts.
- To encourage collaboration across sectors and the sharing of expertise, particularly between developers and regulatory bodies. This project, coordinated by CEA-Tech (Leti and Liten, FR), brings together nine partners from eight different nations:^[36]
 - Joint Research Centre-European Commission (IT)
 - European Research Services GmbH (DE),
 - Leidos Biomedical Research, Inc. (US)
 - Trinity College Dublin (IE)
 - Stiftelsen SINTEF (NO)



- University of Liverpool (UK)
- EMPA (CH) and
- Gesellschaft für Bioanalytik Münster (GE).



Six testing facilities under EU-NCL will give international wangle to their current testing services for public and private builders, and they may also expand new or advanced testing assays to position EU-NCL at the forefront of nanomedicine characterization. With over €5 million allotted, the EU Commission is funding the EU-NCL for a period of 4–12 months.^[37]

MEDICAL DEVICES OF NANOMEDICINE^[38]

To connect and associate computers with the neurological system, neuro-digital interfacing, a futuristic objective, deals with the nuances of nano-devices. This idea calls for molecular-shaped towers to enable control and detection of nerve impulses through the use of an external laptop. The possibility of electrical interference, leakage, or overheating due to energy consumption is one barrier to this breakthrough. Because they must be put precisely inside the concerned gadget, the wiring of the structure is very difficult.


A speculative branch of nanotechnology called molecular nanotechnology explores the potential for creating molecular assemblers, or devices that would reorder information on a molecular or two-bit scale. These new nano-robots could be used in nanomedicine to detect and treat infections and repair damage. In all fairness, molecular nanotechnology is purely theoretical; it aims to forecast the potential benefits of the technology and provide a timeline for

upcoming research. The molecular nanotechnology components that have been proposed, together with molecular assemblers and nano-robots, are a long way cutting-edge technologies.

Upcoming developments in nanomedicine should lead to life extension through the improvement of numerous processes thought to be a surefire cause of aging. In his 1986 book *Engines of Creation*, Drexler *et al.* – one of the pioneers of nanotechnology – posited the idea of cell repair machines, which would function inside cells and use only hypothetical molecular machines. The first technical discussion of scientific nano-robots appeared in 1999, thanks to Robert Freitas. Future thinker and trans-humanist Raymond Kurzweil wrote in his book *The Singularity Is Near* that he expected widespread scientific nano-robotics to effectively address the effects of ageing by the year 2030.

Richard Feynman claims that Albert Hibbs, a former doctoral student and partner, was the one who first suggested (about 1959) the idea of a methodical application for Feynman's theoretical micromachines (see nanotechnology). Hibbs predicted that some repair devices would eventually become so small (as Feynman put it) that they could theoretically “consume the doctor,” to use his phrase. Feynman's 1959 essay *There is Plenty of Space on the Bottom* contains a protected version of the concept.^[39]

USES OF NANOMEDICINE^[40]



Three pillars serve as the foundation for effective

uses of nanotechnology in medicine.

1. Nanomaterials and nano-instruments have potential for use as biosensors, therapeutic aids, and zippy material transporters.
2. Knowledge on molecular drugs related to genetics, genomics, and artificially created or altered microbes.
3. Nanotechnologies that can be employed for quick diagnosis and treatment, for genetic fabric repair and lamina surgery, as well as for boosting plant physiological abilities.

CONCLUSION

According to the range of its applications, nanomedicine and nanoparticles have different physical, chemical, and mechanical properties. Nanomedicine's medical uses have advanced dramatically in recent years. Their unique qualities include nanomedicine's high effectiveness and less hazardous side effects. This review has described how, in addition to the background of nanotechnology, we also talk about medicine delivery. At present, research is being done on biocompatible polymers, particularly liposomes and micelles, which have all of the properties of nanomedicine and can be used to make vaccines, genes, and capsules. Furthermore, pay attention to the ethics of nanomedicine and its widespread use. Adverse medication reactions are reduced with the new type of nanoparticle.

REFERENCES

1. Freitas RA Jr. What is nanomedicine? *Nanomedicine* 2005;1:2-9.
2. Coombs RR, Robinson DW. *Nanotechnology in Medicine and the Biosciences*. Amsterdam: Gordon and Breach; 1996.
3. Nanomedicine Overview. *Nanomedicine*, US National Institutes of Health; 2016 [Last accessed on 2017 Apr 8].
4. Market Report on Emerging Nanotechnology Now Available. Market Report. US: National Science Foundation; 2014. Available from: https://www.nsf.gov/news/news_summ.jsp?cntn_id=130586 [Last accessed on 2016 Jun 07].
5. Ranganathan R, Madanmohan S, Kesavan A, Baskar G, Krishnamoorthy YR, Santosham R, *et al.* Nanomedicine: Towards development of patient-friendly drug-delivery systems for oncological applications. *Int J Nanomedicine* 2012;7:1043-60.
6. LaVan DA, McGuire T, Langer R. Small-scale systems for *in vivo* drug delivery. *Nat Biotechnol* 2003;21:1184-91.
7. Cavalcanti A, Shirinzadeh B, Freitas RA Jr., Hogg T. Nanorobot architecture for medical target identification. *Nanotechnology* 2008;19:015103.
8. Boisseau P, Loubaton B. Nanomedicine, nanotechnology in medicine. *Comptes Rendus Physique* 2011;12:620-36.
9. Rao S, Tan A, Thomas N, Prestidge CA. Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases. *J Control Release* 2014;193:174-87.
10. University of Waterloo, Nanotechnology in Targeted Cancer Therapy. Available from: <https://www.youtube.com/watch?v=RBjWwlnq3cA15> January 2010
11. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. *Science* 2004;303:1818-22.3.
12. Walsh MD, Hanna SK, Sen J, Rawal S, Cabral CB, Yurkovetskiy AV, *et al.* Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. *Clin Cancer Res* 2012;18:2591-602.
13. Minchin R. Nanomedicine: Sizing up targets with nanoparticles. *Nat Nanotechnol* 2008;3:12-3.
14. Banoee M, Seif S, Nazari ZE, Jafari-Fesharaki P, Shahverdi HR, Moballegh A, *et al.* ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against *Staphylococcus aureus* and *Escherichia coli*. *J Biomed Mater Res B Appl Biomater* 2010;93:557-61.
15. Mappes T, Jahr N, Csaki A, Vogler N, Popp J, Fritzsche W. The invention of immersion ultramicroscopy in 1912-the birth of nanotechnology? *Angew Chem Int Ed Engl* 2012;51:11208-12.
16. Nirenberg MW, Matthaei JH. The dependence of cell-free protein synthesis in *E. coli* upon naturally occurring or synthetic polyribonucleotides. *Proc Natl Acad Sci U S A* 1961;47:1588-602.
17. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. *Nature* 1953;171:737-8.
18. Feynman RP. There's plenty of room at the bottom. An invitation to enter a new field of physics. *Eng Sci (Caltech)* 1960;23:22-36.
19. Drexler KE, Peterson C, Pergamit G. *Un Bounding the Future: The Nano Technology Revolution*. Morrow: New York; 1991.
20. Kreuter J. Nanoparticles--a historical perspective. *Int J Pharm* 2007;331:1-10.
21. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 1975;256:495-7.
22. Kateb B, Heiss JD. *The Textbook of Nanoneuroscience and Nanoneurosurgery*. Boca Raton, FL, USA: CRC Press; 2014.
23. Noorlander CW, Kooi MW, Oomen AG, Park MV, Vandebriel RJ, *et al.* Horizon scan of nanomedicinal products. *Nanomedicine (Lond)* 2015;10:1599-608.

24. Donaldson K. Resolving the nanoparticles paradox. *Nanomedicine (Lond)* 2006;1:229-34.
25. Wood AJ, Darbyshire J. Injury to research volunteers--the clinical-research nightmare. *N Engl J Med* 2006;354:1869-71.
26. Bhogal N, Combes R. TGN1412: Time to change the paradigm for the testing of new pharmaceuticals. *Altern Lab Anim* 2006;34:225-39.
27. Cohen SM. Human relevance of animal carcinogenicity studies. *Regul Toxicol Pharmacol* 1995;21:75-80.
28. Toxicity tests in animals: Extrapolating to human risks. *Environ Health Perspect* 1993;101:396-401.
29. Slutsky AS, Lavery JV. Data safety and monitoring boards. *N Engl J Med* 2004;350:1143-7.
30. News Release. FDA Approves New Treatment for Advanced Pancreatic Cancer. Maryland: FDA; 2015.
31. Gibney M. Cornell Nanosized 'dots' for Diagnostics May Now Deliver Drugs; 2013. Available from: <https://fiercedrugdelivery.com> [Last accessed on 2013 Jun 17].
32. Elvidge S. Bacterial 'Minicells' Deliver Cancer Drugs Straight to the Target; 2012. Available from: <https://fiercedrugdelivery.com> [Last accessed on 2012 Dec 10].
33. First Trial in Humans of 'Minicells': A Completely New Way of Delivering anti-Cancer Drugs. Available from: <https://fiercedrugdelivery.com> [Last accessed on 2012 Nov 12].
34. Press Release. Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease (PDF). United States: Kala Pharmaceuticals; 2014.
35. Available from: https://encryptedtbn0.gstatic.com/images?q=tbn:ANd9GcSw5PEYkJ2PZ11V0Nt_MqHCDyNFeMPy7Q63KzA_pMsd_Hm8j9hT8g
36. Available from: <https://www.epmmagazine.com/news/european-nanomedicine-characterisation-laboratory> [Last accessed on 2017 Nov 01].
37. Freitas RA Jr. *Nanomedicine, Volume IIA: Biocompatibility*. United States: CRC Press; 2003.
38. Freitas RA Jr. Current status of nanomedicine and medical nanorobotics. *J Comput Theor Nanosci* 2005;2:1-25.
39. Kurzweil R. *The Singularity is Near*. New York City: Viking Press; 2005.
40. Feynman RP. *There's Plenty of Room at the Bottom*. Michigan: Michigan State University; 1959 [Last accessed on 2010 Mar 26].